WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the company will present at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023. Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon, will present as part of the private company track at 2:10 p.m. EST at the St. Regis New York hotel, and Palleon will participate in 1x1 investor meetings during the event.
About Palleon Pharmaceuticals
Palleon Pharmaceuticals, co-founded by Nobel laureate Carolyn Bertozzi, is a biotechnology company pioneering glyco-immunology drug development to transform the treatment of cancer and inflammatory diseases. The Company’s proprietary platforms overcome technical barriers unique to glycobiology to enable drug discovery, patient selection, and indication prioritization to de-risk clinical development. The company’s lead program in oncology, E-602, is a first-in-class, glyco-immune checkpoint inhibitor which restores antitumor immunity by enzymatically degrading immunosuppressive sialoglycans on hypersialylated tumors and immune cells. It is being evaluated in a Phase 1/2 clinical trial. Palleon has a rich pipeline of additional drug candidates including several advancing toward IND-enabling studies.
